 | Up a level |
Aoki, Naomi and Chen, Pin-Yen and Chen, Wenming and Chng, Wee Joo and Gan, Gin Gin and Goh, Yeow Tee and Hou, Jian and Huang, Jeffrey and Kim, Kihyun and Lee, Je Jung and Lu, Jin and McQuilten, Zoe K. and Min, Chang Ki and Moore, Elizabeth and Oliver, Laura and Waters, Neil A. and Wellard, Cameron and Wood, Erica M. and Yeh, Su-Peng and Spencer, Andrew and Investigators, APAC MRDR (2024) The establishment of a multiple myeloma clinical registry in the Asia-Pacific region: The Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR). BMC Medical Research Methodology, 24 (1). p. 102. ISSN 1471-2288, DOI https://doi.org/10.1186/s12874-024-02227-0.
Chan, Jia Jia and Zhang, Bin and Chew, Xiao Hong and Salhi, Adil and Kwok, Zhi Hao and Lim, Chun You and Desi, Ng and Subramaniam, Nagavidya and Siemens, Angela and Kinanti, Tyas and Ong, Shane and Sanchez-Mejias, Avencia and Ly, Phuong Thao and An, Omer and Sundar, Raghav and Fan, Xiaonan and Wang, Shi and Siew, Bei En and Lee, Kuok Chung and Chong, Choon Seng and Lieske, Bettina and Cheong, Wai-Kit and Goh, Yufen and Fam, Wee Nih and Ooi, Melissa G. and Koh, Bryan T. H. and Iyer, Shridhar Ganpathi and Ling, Wen Huan and Chen, Jianbin and Yoong, Boon-Koon and Chanwat, Rawisak and Bonney, Glenn Kunnath and Goh, Brian K. P. and Zhai, Weiwei and Fullwood, Melissa J. and Wang, Wilson and Tan, Ker-Kan and Chng, Wee Joo and Dan, Yock Young and Pitt, Jason J. and Roca, Xavier and Guccione, Ernesto and Vardy, Leah A. and Chen, Leilei and Gao, Xin and Chow, Pierce K. H. and Yang, Henry and Tay, Yvonne (2022) Pan-cancer pervasive upregulation of 3 ` UTR splicing drives tumourigenesis. Nature Cell Biology, 24 (6). 928+. ISSN 1465-7392, DOI https://doi.org/10.1038/s41556-022-00913-z.
Koschut, David and Ray, Debleena and Li, Zhenhua and Giarin, Emanuela and Groet, Jurgen and Alic, Ivan and Kham, Shirley Kow-Yin and Chng, Wee Joo and Ariffin, Hany Mohd and Weinstock, David M. and Yeoh, Allen Eng-Juh and Basso, Giuseppe and Nizetic, Dean (2021) RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia. Oncogene, 40 (4). pp. 746-762. ISSN 0950-9232, DOI https://doi.org/10.1038/s41388-020-01567-7.
